Dicinone 250 mg tablets, No. 50 (5 x 10), 5 blister packs

In stock: 6
$65.00

Ingredients

Active ingredient: etamsylate;

1 tablet contains 250 mg of etamsylate;

Inactive ingredients: anhydrous citric acid, cornstarch, lactose monohydrate, povidone, magnesium stearate.

Dosage Form

Tablets.

Main physical and chemical properties: white or almost white, round, biconvex tablets.

Pharmacotherapeutic group

Antihemorrhagic agents. Other hemostatic agents for systemic use.

ATC code B02B X01.

Pharmacological properties

Pharmacodynamics.

Etamsylate is an agent used to prevent and stop bleeding. It acts on the first stage of the hemostatic mechanism (the interaction between the endothelium and platelets). Dicynone increases platelet adhesion, normalizes the integrity of capillary walls, thereby reducing their permeability, and inhibits the biosynthesis of prostaglandins, which cause platelet disaggregation, vasodilation, and increased capillary permeability. As a result, bleeding time is significantly reduced, and blood loss is minimized.

Pharmacokinetics.

Etamsylate is almost completely absorbed in the gastrointestinal tract, reaching peak serum concentrations 4 hours after administration. Approximately 95% of the drug binds to plasma proteins.

Approximately 72–80% of the administered dose is excreted unchanged in the urine within the first 24 hours. Etamsylate crosses the placental barrier. It is unknown whether etamsylate is excreted into breast milk.

Indications

Dicinon is indicated for the prevention and control of bleeding in superficial and internal capillaries of various etiologies, especially when bleeding is caused by endothelial damage:

  • prevention and treatment of bleeding during and after surgical procedures in otolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology, and plastic surgery;
  • prevention and treatment of capillary bleeding of various etiologies and locations: hematuria, metrorrhagia, primary hypermenorrhea, hypermenorrhea in women with intrauterine contraceptive devices, nosebleeds, and gingival bleeding.

Contraindications

Hypersensitivity to etamsylate or to any other component of the drug. Acute porphyria, hypercoagulability, thrombosis, thromboembolism. Hematological malignancies (lymphocytic and myeloid leukemia, osteosarcoma) in children.

Interactions with Other Medications and Other Types of Interactions

Administration of etamsylate prior to the administration of dextrans (e.g., Reopoliglukin) prevents their antiplatelet effect; after the administration of dextrans, it does not exert a hemostatic effect. Interactions with aminocaproic acid and Vikasol are permissible.

Special Considerations for Use

Use the drug with caution in patients with a history of thrombosis or thromboembolism. The drug is ineffective in patients with low platelet counts.

In cases of hemorrhagic complications associated with anticoagulant overdose, the use of specific antidotes is recommended.

Before starting treatment, other causes of bleeding should be ruled out. If no improvement is observed when using Dicynone to reduce excessive and/or prolonged menstrual bleeding, possible pathological causes (e.g., the presence of uterine fibroids) must be ruled out.

If skin reactions or fever occur, treatment should be discontinued and a doctor consulted, as this may be a sign of hypersensitivity.

This medication contains lactose; therefore, patients with rare hereditary forms of galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take Dicynon.

Use in patients with renal impairment.

The safety and efficacy of etamsylate have not been studied in patients with renal insufficiency. Since etamsylate is almost entirely excreted by the kidneys, the dose of the drug should be reduced in cases of renal insufficiency.

Laboratory Tests.

At therapeutic doses, etamsylate may lower creatinine levels in laboratory tests.

Use during pregnancy or breastfeeding.

There are no reliable data on the effects of Dicynon on the fetus; therefore, the drug is contraindicated during the first trimester of pregnancy. During the second and third trimesters of pregnancy, the drug may be used if the benefit to the mother outweighs the risk to the fetus.

Breastfeeding should be discontinued while taking this medication.

Effect on reaction time when driving or operating machinery.

It has no effect, but dizziness may occur while taking the drug, which should be taken into account when driving or operating machinery.

Dosage and Administration

Take orally. Take the tablets during or after meals with a small amount of water.

The daily dose for adults is usually 2 tablets 2–3 times a day (1,000–1,500 mg).

Before surgery, take 1–2 tablets (250–500 mg) 1 hour before the procedure.

After surgery, take 1–2 tablets (250–500 mg) every 4–6 hours until the risk of bleeding has subsided.

For menorrhagia, take 2 tablets 3 times a day (1,500 mg) for 10 days, starting on the 5th day from the expected start of menstruation until the 5th day of the next menstrual cycle.

The daily dose for children is half the adult dose.

Patients with hepatic or renal insufficiency should use this medication with caution.

Children.

This medication is indicated for children 6 years of age and older. Do not administer to children with hemoblastosis.

Overdose

No data available. In case of overdose, treatment is symptomatic.

Side Effects

Nervous system: headache, dizziness, hot flashes, paresthesia of the lower extremities.

Gastrointestinal system: nausea, vomiting, diarrhea, abdominal discomfort.

Immune system: hypersensitivity, allergic reactions, skin rash, hives, itching; a case of angioedema has been reported.

Musculoskeletal system: arthralgia.

Blood and lymphatic system disorders: agranulocytosis, neutropenia, thrombocytopenia.

Vascular system: thromboembolism.

Other: asthenia, fever, acute porphyria.

All side effects are mild and transient.

In children treated with etamzilate to prevent bleeding in acute lymphocytic and myeloid leukemia, severe leukopenia was observed more frequently.

Shelf life

5 years.

Storage conditions

Store at a temperature not exceeding 25 °C in the original packaging.

Keep out of reach of children.

Packaging

10 tablets per blister; 10 (10 × 10) blisters per cardboard box.

Manufacturer

Lek Pharmaceutical Company d. d.

Address

Verovškova 57, Ljubljana 1526, Slovenia (full-cycle manufacturing);

Trimlini 2D, 9220 Lendava, Slovenia (primary and secondary packaging, batch release authorization).